A Targeted Alpha Particle Radiopharmaceutical for Bone Metastatic Breast Cancer
Technical Report,01 Apr 2019,31 Mar 2020
Wake Forest University Health Services Winston-Salem United States
Pagination or Media Count:
The proposed studies will develop and evaluate a new therapeutic strategy for treating breast cancer bone metastasis by disrupting the interactions between breast cancer cells and sensory neurons within bone using alpha particle-emitting radiopharmaceuticals that target the CGRP-CRLR axis. The successful completion of this project will establish a new therapeutic target for cancer-induced bone pain and bone metastatic breast cancer while providing the foundation required to develop new therapies that will decrease suffering and improve survival of breast cancer patients with bone metastases. During this period, Dr. Wadas accepted a new position at the University of Iowa as an Associate Professor of Radiology, the Director of the Small Animal Imaging Center and the Managing Director of the clinical Theranostics Center. This cGMP laboratory employs a production team of five radio-and analytical chemists and produces radiotherapies for clinical use. He has successfully completed the transfer of his partnering award BC180720P1 to the University of Iowa. Before Dr. Wadas move, the research team found that 225Ac-PTCA-CGRP27-37 was stable in human serum. The team also developed CRLC down-regulated BCa cells which will be used to test in vitro biding affinity of 225Ac-PTCA-CGRP27-37 to CRLR in the next year.
- Medicine and Medical Research